Sirnaomics Spinoff to develop mRNA drugs

By The Science Advisory Board staff writers

June 12, 2020 -- Sirnaomics announced a spinoff establishing an independent biopharmaceutical company, RNAimmune.

The new firm will focus on and specialize in messenger RNA (mRNA)-based therapeutics and vaccine development, with exclusively licensed polypeptide-lipid nanoparticle delivery technology and large-scale good manufacturing practices knowledge from Sirnaomics. RNAimmune will also focus on a proprietary artificial intelligence algorithm for epitope prediction and validation.

RNAimmune plans to develop a vaccine for COVID-19 with a unique mRNA vaccine design and mRNA delivery under the leadership of Dr. Dong Shen, PhD. Shen previously led projects across multiple therapeutic areas at AstraZeneca and Johnson & Johnson.

Sirnaomics will have the right to retain an equity investment in RNAimmune, the firm said.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter